Merck Trails Peers Into Monday's Print With the Street Split on Keytruda's Ceiling

MRK gained 1.4% over the past week, closing Thursday at $147.24, but that move lagged its closest pharmaceutical peers by nearly two percentage points. JNJ added 1.5%, LLY rose 5.1%, and BMY climbed 3.1% over the same period. The relative underperformance is the clearest signal heading into Monday's Q3 results, not alarm, but a gap that frames the market's skepticism about near-term catalysts.

Short interest is not the story here. At 1.18% of free float, it has drifted down roughly 15% from its mid-September peak and sits near a two-month low. Borrow availability is effectively unlimited, with the lending pool barely touched, and cost to borrow remains negligible at 0.43%. Options positioning is similarly calm: the put/call ratio of 0.77 is slightly below its 20-day average of 0.79, a fraction of a standard deviation from normal. Nothing in the positioning data suggests traders are bracing for a shock.

The debate is concentrated entirely on Keytruda and what comes after it. The bull case rests on a diversified commercial base anchored by Keytruda, with Winrevair, Capvaxive, and animal health adding breadth, and Phase 3 successes for sacTMT and tulisokibart materially improving the pipeline's odds of filling the revenue gap when Keytruda's exclusivity expires in 2028 to 2029. Analysts at Morgan Stanley and JP Morgan hold Overweight ratings, with targets of $177 and $165 respectively, both raised in the weeks ahead of this print. The bear case is more immediate: Keytruda's U.S. trends are only moderate, mandatory German rebates and price-volume agreements in Europe are biting, and Januvia/Janumet revenue is eroding faster as IRA pricing kicks in alongside generic competition. Citigroup and RBC both hold neutral-equivalent ratings with targets of $145, essentially at the current price, after moving in opposite directions on their targets in mid-October. The mean analyst target of $158.56 implies roughly 8% upside from current levels, but that average is stretched by the bullish outliers at Scotiabank ($180) and HSBC ($172).

Medicaid prescription data from the Centers for Medicare and Medicaid Services adds one unflattering data point to the mix. Merck's Medicaid prescriptions ran 22% below the same quarter a year earlier in Q1 2026, with Medicaid units reimbursed down 16% over the same comparison. The dataset is not a verified leading indicator for reported revenues, so it cannot be read as a forecast of the Q3 print. But it does put a number on the IRA-driven volume pressure that bears have been citing in analyst notes.

The Q3 earnings call on October 26 is therefore less about whether Keytruda is growing and more about the degree to which management's updated guidance for 2026 and 2027 acknowledges the patent cliff, and whether the pipeline readouts from the back half of the year are enough to justify the gap between the $145 cautious camp and the $165-plus optimists.